* Target Lesion Failure. Composite of cardiac and unknown death, Target-Vessel Myocardial Infarction, Clinically-Driven Target Lesion revascularization and emergent CABG.
** Four out of five cases having early DAPT or anticoagulant interruption at post procedure.
1. Joner M, Ruppelt P, Zumstein P, et al. Preclinical Evaluation of Degradation Kinetics and Elemental Mapping of First and Second Generation Bioresorbable Magnesium Scaffolds. EuroIntervention. 2018 Feb 20. pii: EIJ-D-17-00708. doi: 10.4244/EIJ-D-17-00708; 2. Haude M, Ince H, Kische S, et al. Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 12-month follow-up- BIOSOLVE-II and BIOSOLVE-III. Journal of the American College of Cardiology. 2017; 70(18). DOI: 10.1016/j.jacc.2017.09.071; 3. Haude M, Ince H, Abizaid A, et al. Long-term clinical data and multimodality imaging analysis of the BIOSOLVE-II study with the drug-eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries – BIOSOLVE-II. Presented at: EuroPCR; May 23, 2018; Paris. France; 4. Stone, G. Everolimus-Eluting Stents: SPIRIT and PLATINUM Update. Presented at: TCT; Oct 22-26, 2012; Miami, USA. ClinicalTrials.gov: NCT00180310 .NCT00180479, NCT00307047; 5. EVOLVE FHU 24m: Meredith I, Verheye S, Weissmann N, et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013; 9: 308-315; 6. BIOTRONIK data on file; 7. Schmidt W, Behrens P, Brandt-Wunderlich C, et al. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond. Cardiovasc Revasc Med. 2016;17(6):375-83. doi: 10.1016/j.carrev.2016.05.001; 8. Hideo-Kajita A, Garcia-Garcia H, Azizi V. Comparison of Clinical Outcomes Between Magmaris (Dreams 2G) and Orsiro Drug Eluting Stent: Pooled Patient Level Analysis From Biosolve II-III and Bioflow II Trials. Presented at ACC; March 10, 2018; Orlando, USA; 9. BIOSOLVE-II case, GER443-012. Courtesy of M. Haude, Lukaskrankenhaus Neuss, Germany 2015; 10. Lipinski MJ, Acampado E, Cheng Q, et al.Comparison of Acute Thrombogenicity for Magnesium versus Stainless Steel Stents in a Porcine Arteriovenous Shunt Model. EuroIntervention. 2018 May 8. pii: EIJ-D-17-00958. doi: 10.4244/EIJ-D-17-00958; 11. Nakazawa G, Vorpahl M, Finn M, et al. One Step Forward and Two Steps Back With Drug-Eluting-Stents. JACC: Cardiovascular Imaging . 2009; 2(5): 625-628. DOI: 10.1016/j.jcmg.2009.01.011; 12. Joner M. Systemic vs Site Targeted Treatment of Neoatherosclerosis. Presented at: ESC; Aug 28, 2017; Barcelona, Spain; 13. Andreou I, Stone P. In-Stent Atherosclerosis at a Crossroads. Neoatherosclerosis or Paleoatherosclerosis? Circulation. 2016;134:1413–1415. DOI: 10.1161/CIRCULATIONAHA.116.025129; 14. Verheye S. Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry. Presented at: TCT; September 25, 2019; San Francisco; USA. NCT02817802; (n=2,054; 1,075 patients presented); 15. Haude M. Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 36-month Follow-up-BIOSOLVE-II and -III, Presented at: TCT; September 27, 2019; San Francisco, USA; 16. Haude M, Erbel R, Erne, et al. Safety and performance of the Drug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicenter, first-in-man BIOSOLVE-I trial. EuroIntervention. 2016; 12(2): e160-e166; 17. Joner M. Magmaris: Reducing the risk of neoatherosclerosis. Presented at: TCT; Sep 22, 2018; San Diego, USA. Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies. Xience is a trademark or registered trademark of the Abbott Group of Companies. Synergy is a trademark or a registered trademark of the Boston Scientific Group of Companies.
© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.